These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15221148)

  • 1. [Isoforms of free prostate-specific antigen].
    Haese A; Noldus J; Steuber T; Huland H; Lilja H
    Urologe A; 2004 Jun; 43(6):675-9. PubMed ID: 15221148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
    Haese A; Graefen M; Palisaar J; Huland E; Huland H
    Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of total, complexed and free prostate-specific antigens and their ratios in the detection of prostate cancer in a non-screened population.
    McArdle PA; Pollock MA; Wallace AM; McMillan DC; Crooks JE; Underwood MA
    Ann Clin Biochem; 2004 May; 41(Pt 3):201-6. PubMed ID: 15117433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer.
    Mitchell ID; Croal BL; Dickie A; Cohen NP; Ross I
    J Urol; 2001 May; 165(5):1549-53. PubMed ID: 11342915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the diagnostic use of free prostate specific antigen/total prostate specific antigen ratio in detecting prostate cancer.
    Iqbal N; Chaughtai N
    J Pak Med Assoc; 2005 Aug; 55(8):318-20. PubMed ID: 16164156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond PSA: a need for additional markers for prostate cancer.
    Sartor O
    Clin Prostate Cancer; 2004 Dec; 3(3):135. PubMed ID: 15636677
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
    Stephan C; Jung K; Lein M; Sinha P; Schnorr D; Loening SA
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1133-47. PubMed ID: 11097220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of prostate specific antigen and its derivatives (age-specific PSA, PSA density, velocity, free/total PSA) in the diagnosis of prostate cancer].
    Di Silverio F; D'Eramo G; Buscarini M; Sciarra A; Casale P; Di Nicola S; Loreto A
    Minerva Urol Nefrol; 1998 Jun; 50(2):143-54. PubMed ID: 9707970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
    Catalona WJ; Bartsch G; Rittenhouse HG; Evans CL; Linton HJ; Amirkhan A; Horninger W; Klocker H; Mikolajczyk SD
    J Urol; 2003 Dec; 170(6 Pt 1):2181-5. PubMed ID: 14634374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The percentage of free prostate specific antigen used in detecting prostate cancer].
    Yang L; Fang Z; Song J; Deng S
    Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination and multivariate analysis of PSA-based parameters for prostate cancer prediction.
    Djavan B; Remzi M; Zlotta AR; Seitz C; Wolfram R; Hruby S; Bursa B; Schulman CC; Marberger M
    Tech Urol; 1999 Jun; 5(2):71-6. PubMed ID: 10458658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of total prostate specific antigen and free to total prostate specific antigen ratio in the diagnosis of prostate cancer.
    Chakraborty L; Ahmed AN; Paul BK; Haque A; Ara A; Nabi S; Nessa M
    Mymensingh Med J; 2012 Jan; 21(1):98-102. PubMed ID: 22314462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The search for better markers for prostate cancer than prostate-specific antigen].
    Schenk-Braat EA; Bangma CH
    Ned Tijdschr Geneeskd; 2006 Jun; 150(23):1286-90. PubMed ID: 16821452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategy for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic analysis: a step towards diagnosis of prostate cancer.
    Kumar V; Hassan MI; Singh AK; Dey S; Singh TP; Yadav S
    Clin Chim Acta; 2009 May; 403(1-2):17-22. PubMed ID: 19118539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
    Van Cangh PJ; De Nayer P; Sauvage P; Tombal B; Elsen M; Lorge F; Opsomer R; Wese FX
    Prostate Suppl; 1996; 7():30-4. PubMed ID: 8950361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.